Literature DB >> 11115055

Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups.

H B Krarup1, J M Møller, P B Christensen, T Fuglsang, J Ingerslev, T Arnfred, P H Madsen.   

Abstract

Comparison of hepatitis C viral load between different patient populations has been hampered by the use of different technology in individual studies. We had the impression that haemophilic (HAEM) patients had a higher serum load of hepatitis C virus (HCV) compared to other HCV-infected patients. We therefore studied viral load and genotypes in active illicit drug users (IDU), HAEM patients and patients with post-transfusion hepatitis (PTH). The study comprises 225 HCV-RNA positive patients, 117 IDU, 60 HAEM patients and 48 PTH patients. All patients were anti-HIV negative. HCV-RNA was measured with a quantitative reverse transcription polymerase chain reaction (RT-PCR) method, HCV-genotypes were determined with genotype specific primers in RT-PCR in 221 patients. Four patients could not be genotyped with our assay and were excluded. Overall viral load was higher in genotypes 1 and 2 compared to genotype 3, median values of HCV-RNA were 1,400 x 10(3) geq ml(-1), 2,700 x 10(3) geq ml(-1) and 270 x 10(3) geq ml(-1), respectively. HAEM patients had significantly higher viral load for both genotypes 1 and 3 compared to the IDU and PTH patients. In a multiple linear regression model HCV-RNA viral load was independently associated with HAEM and genotype, but not to age, gender or disease duration. In conclusion, HAEM patients have higher viral load than IDU and PTH patients. The reason for this is unknown, but it may be due to host factors or mode of transmission with multiple inoculations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115055     DOI: 10.1046/j.1365-2893.2000.00258.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.

Authors:  Nanna Hansen; Niels Obel; Peer B Christensen; Mette Kjær; Alex L Laursen; Henrik B Krarup; Axel Møller; Poul Schlichting; Jens Bukh; Nina Weis
Journal:  BMC Infect Dis       Date:  2011-06-21       Impact factor: 3.090

3.  Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.

Authors:  Christina Sølund; Henrik Krarup; Santseharay Ramirez; Peter Thielsen; Birgit T Røge; Suzanne Lunding; Toke S Barfod; Lone G Madsen; Britta Tarp; Peer B Christensen; Jan Gerstoft; Alex L Laursen; Jens Bukh; Nina Weis
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

4.  Influence of hepatitis C virus and IL28B genotypes on liver stiffness.

Authors:  Lene Fogt Lundbo; Louise Nygaard Clausen; Nina Weis; Kristian Schønning; Lene Rosenørn; Thomas Benfield; Peer Brehm Christensen
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.